SB17170 Phase 2 Trial in IPF Patients

על הניסוי

This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by administering SB17170 to moderate to severe patients with IPF. This clinical trial treatment involves administering SB17170 or placebo for 12 weeks.

צפו ב-NCT06747923 ב-ClinicalTrials.gov ←

קישורים קשורים